TSE:PMN ProMIS Neurosciences (PMN) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free PMN Stock Alerts Add Compare Share Share Today's Range N/A50-Day RangeC$6.00▼C$6.0052-Week Range N/AVolume19,701 shsAverage Volume3,327 shsMarket CapitalizationC$51.48 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisEarningsHeadlinesInsider TradesStock AnalysisEarningsHeadlinesInsider Trades Get ProMIS Neurosciences alerts: Email Address Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About ProMIS Neurosciences Stock (TSE:PMN)ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.Read More Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… PMN Stock News HeadlinesApril 1, 2024 | msn.comPMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q4 2023February 22, 2024 | finance.yahoo.comProMIS Neurosciences to Present at the 2024 BIO CEO & Investor ConferenceApril 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.February 1, 2024 | msn.comNerve stimulation plus physical rehabilitation may boost recovery of arm and hand functionJanuary 8, 2024 | markets.businessinsider.comProMIS Neurosciences Issues Letter to ShareholdersDecember 20, 2023 | finanznachrichten.deProMIS Neurosciences Inc.: ProMIS Neurosciences Announces Publication on Novel Target for ALSNovember 20, 2023 | markets.businessinsider.comProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s DiseaseNovember 14, 2023 | finance.yahoo.comProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent HighlightsApril 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.September 8, 2023 | finance.yahoo.comProMIS Neurosciences Closes $20.4 Million Private Placement FinancingAugust 22, 2023 | marketwatch.comProMIS Neurosciences Shares Jump on $20.4 Million Private PlacementAugust 15, 2023 | finanznachrichten.deProMIS Neurosciences Inc.: ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent HighlightsAugust 14, 2023 | finance.yahoo.comProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent HighlightsAugust 1, 2023 | seekingalpha.comPMN ProMIS Neurosciences, Inc.July 17, 2023 | marketwatch.comToronto Stocks Edge Lower; ProMIS Neurosciences Soars on Positive Alzheimer's Treatment DataJuly 17, 2023 | msn.comAlzheimer’s Drug Data Sends ProMIS Vaulting UpJuly 17, 2023 | msn.comWhy ProMIS Neurosciences Stock Surged TodayJuly 17, 2023 | msn.comProMIS stock rockets 115% amid preclinical data for Alzheimer's drugJuly 17, 2023 | finance.yahoo.comProMIS Showcases Preclinical Data at the Alzheimer’s Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer’s PipelineJuly 14, 2023 | finance.yahoo.comProMIS Announces Completion of ContinuanceJuly 10, 2023 | finanznachrichten.deProMIS Neurosciences Inc.: ProMIS Neurosciences to Consolidate Trading on the Nasdaq ExchangeJuly 10, 2023 | finance.yahoo.comProMIS Neurosciences to Consolidate Trading on the Nasdaq ExchangeJune 30, 2023 | finance.yahoo.comProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions ApprovedJune 29, 2023 | finance.yahoo.comCORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern TimeMay 16, 2023 | finanznachrichten.deProMIS Neurosciences Inc.: ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent HighlightsMay 8, 2023 | finance.yahoo.comProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer’s DiseaseApril 27, 2023 | theglobeandmail.comClosing Bell: Promis Neurosciences Inc up on Wednesday (PMN)See More Headlines Receive PMN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProMIS Neurosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolTSE:PMN Previous SymbolTSE:AMF CUSIPN/A CIKN/A Webwww.promisneurosciences.com Phone+1-416-8476898FaxN/AEmployees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($3.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-20,930,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-837.71% Return on Assets-168.33% Debt Debt-to-Equity Ratio108.33 Current Ratio0.51 Quick Ratio1.30 Sales & Book Value Annual SalesC$7,558.00 Price / Sales0.00 Cash FlowN/A Price / Cash Flow14.07 Book ValueC($0.72) per share Price / BookN/AMiscellaneous Outstanding Shares8,580,000Free FloatN/AMarket CapC$51.48 million OptionableNot Optionable Beta1.19 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Eugene Williams (Age 64)Co-Founder & Chairman Comp: $439.21kDr. Gail M. Farfel Ph.D. (Age 59)CEO & Director Comp: $177.23kDr. Neil R. Cashman M.D. (Age 71)Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director Comp: $333.8kMr. Gavin T. Malenfant (Age 59)Chief Operating Officer Comp: $413.49kMr. Daniel E. Geffken M.B.A. (Age 66)MBA, Chief Financial Officer Dr. Johanne Kaplan Ph.D. (Age 63)Chief Devel. Officer Dr. Ernest D. Bush Ph.D.Head of Pharmacology/Toxicology & Sr. ConsultantDr. David Wishart Ph.D.Chief Physics OfficerMr. Dennis Chen Ph.D.Head of Manufacturing & Sr. ConsultantDr. Larry Douglas Altstiel M.D. (Age 73)Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsEmerald Health TherapeuticsCVE:EMHSmall PharmaCVE:DMTBriaCell TherapeuticsTSE:BCTMicrobix BiosystemsTSE:MBXHelix BioPharmaTSE:HBPView All Competitors PMN Stock Analysis - Frequently Asked Questions What other stocks do shareholders of ProMIS Neurosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other ProMIS Neurosciences investors own include CRISPR Therapeutics (CRSP), Aurora Cannabis (ACB), Biocept (BIOC), Spectra7 Microsystems (SEV), Flexion Therapeutics (FLXN), Onconova Therapeutics (ONTX), TherapeuticsMD (TXMD), Bonavista Energy Co. (BNP.TO) (BNP) and QEP Resources (QEP). How do I buy shares of ProMIS Neurosciences? Shares of PMN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:PMN) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority Goldtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProMIS Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
